Group items matching

in title, tags, annotations or url

Dry eye disease, also known as dry eye syndrome, occurs when the eye stops producing enough tears, the tears that are made are of poor quality or the tears evaporate faster than they should. This causes dryness and irritation of the surface of the eye and results in inflammation, discomfort, and damage.[i] Symptoms include dry, red, itchy or tired eyes, blurred vision and foreign body sensation. From over-the-counter eye drops and heated eye masks, to eyelid-cleansing wipes, there are a multitude of options that can be offered to sufferers to provide relief. As a result of the pandemic and new living and working patterns, the World Health Organization has indicated dry eye disease is on the rise. This can be attributed to various lifestyle factors including increased screen use and wearing of face masks. An increase in sufferers seeking advice on the condition in pharmacies has also been reported. It is no surprise that sufferers will turn to their pharmacists for help, support and information on the condition and how it can be managed by treatment options available over-the-counter.

The European Union's health regulator on Friday said it had recommended granting a conditional marketing authorisation for a gene therapy by Australian drugmaker CSL Ltd and partner uniQure N.V. , to treat haemophilia B, a rare bleeding disorder which is caused by genetic anomalies. About one in 40,000 people are affected by the inherited disorder, caused by a gene mutation that hampers the body's ability to make clotting protein factor IX. If approved, the treatment, branded Hemgenix, will be the first gene therapy in the European Union for the condition that is usually treated by regular injections of factor IX, the European Medicines Agency said. CSL had acquired exclusive global rights to Hemgenix in May last year from uniQure N.V.

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer. "There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS," said NICE. The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment. Helen Knight, director of medicines evaluation at NICE, said: "Today's draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

Researchers are curious about curcumin to create an effective anti-infection therapeutic effect and control fungal infections in cancer patients. Curcumin could grow the fungal infection sustainability among cancer patients with candida. Thus, turmeric curcumin supplements offer a reasonably 'secure cure' against candida with minimal or no adverse effects, even when using a higher curcumin dose.

FlowForce Max is an innovative, natural and effective way to address your prostate problems, while adding your energy, libido, and vitality. An impeccably cured personal mix of precisely named plants and minerals, crafted and mixed to complement one another into an important prostate supporting formula. Produced in FDA- approved, GMP- certified installations, each bottle of this nutritive supplement comes with 30 tablets. So, if you follow the instructions given by the manufacturers, it also claims to be an each-natural, GMO-free supplement.